Trial
NCT02016534
Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Amgen
Collaborators
—
Condition
Stomach Neoplasms
Intervention
AMG 337
Why stopped
Amgen decision following interim review of efficacy and safety data from the AMG 337 program.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-07-02